Navigation Links
YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy

that nimotuzumab binds to the receptor, while the independent data from Kinki and Kyoto demonstrated the synergistic effect of nimotuzumab and radiation on cancer cells and inhibition of EGFr down-stream signaling in the presence of nimotuzumab."

"We conclude that nimotuzumab behaves no differently than the other EGFr-targeting antibodies and that the limited and rare incidences of the debilitating side-effects that are commonly seen with other antibodies and small molecules targeting the tyrosine kinase pathway indicates that nimotuzumab has the prospect of being "best-in-class" without compromised efficacy," said David Allan, Chairman and CEO of YM BioSciences.

About nimotuzumab

Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFr). Nimotuzumab has been sub-licensed by CIMYM BioSciences, a subsidiary of YM, to Daiichi Sankyo Co., Ltd for Japan and to other companies advancing the drug including Oncoscience AG in Europe, Kuhnil in South Korea and Innogene Kalbiotech in Southeast Asia. Nimotuzumab is approved for sale in India and China as well as certain Latin American countries for the treatment of head and neck cancers.

YM BioSciences has previously announced its intention to initiate trials with nimotuzumab in colorectal cancer and glioma, for which it has received No Objection letters from Health Canada. YM also recently announced the receipt of a No Objection Letter from Health Canada and a positive certificate of inspection from a competent authority in the EU for the scaled-up manufacturing of the drug at the Center of Molecular Immunology and also announced an expected further doubling of manufacturing capacity at that facility during 2007.

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monocl
'"/>




Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
3. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
4. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:10/8/2008)... LYON, France, Oct. 8 /- Vical Inc...anded clinical data and new nonclinical data,demon...may be broadly,applicable in DNA- and protein-base...ncer vaccines. Alain P. Rolland, Pharm.D., Ph.D., ...nt, will present the data today,Wednesday, Octobe...
(Date:10/7/2008)... SAN DIEGO, Oct. 7 /- Prometheus L...ny, today announced findings from its,development ...y blood test,for irritable bowel syndrome (IBS). T...expression of particular biomarkers in blood sampl...ation of these biomarkers,combined with a proprie...
(Date:10/7/2008)...Study evaluates the efficacy of new device for det...ssed during colonoscopy, ORLANDO, Fla., Oct. 7 /P...erology Annual Scientific Meeting in Orlando (ACG ... MD presented results from a,multi-institutional c...hird,Eye(R) Retroscope(R), a new device that is de...
(Date:10/7/2008)... Results of FLEXX Trial Presented at the Osteoa...ld Congress, PARSIPPANY, N.J., Oct. 7 /PRNewswire...ed results from the FLEXX Trial of Osteoarthritis ...yaluronate), a highly pure,non-avian high molecula...IA-HA), is superior to intra-articular saline (IA-...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4Continua Health Alliance Provides Insight Into Next Generation of Digital Health at CONNECTIONS 28TM 29 20074 1Continua Health Alliance Provides Insight Into Next Generation of Digital Health at CONNECTIONS 28TM 29 20074 2North Castle Partners Names Dennis Lee of Octane Fitness CEO of the Year 20071 1North Castle Partners Names Dennis Lee of Octane Fitness CEO of the Year 20071 2North Castle Partners Names Dennis Lee of Octane Fitness CEO of the Year 20071 3Key to Angelina Like Cheeks 3F Add Volume to Deep Fat Compartment 20068 1Key to Angelina Like Cheeks 3F Add Volume to Deep Fat Compartment 20068 2Advanced Life Sciences Selected as Founding Member of the New NASDAQ OMX AeA Illinois Tech Index 5589 1Advanced Life Sciences Selected as Founding Member of the New NASDAQ OMX AeA Illinois Tech Index 5589 2Advanced Life Sciences Selected as Founding Member of the New NASDAQ OMX AeA Illinois Tech Index 5589 3Advanced Life Sciences Selected as Founding Member of the New NASDAQ OMX AeA Illinois Tech Index 5589 4
(Date:10/10/2008)...e testing is often on those already on drugs, some..., FRIDAY, Oct. 10 (HealthDay News) -- A new study ... Clostridium difficile ( C. difficile ) infections...rchers with McGill University and the Jewish Gener...senior citizens who acquired C. difficile infect...
(Date:10/10/2008)...MONTVALE, N.J., Oct. 10 /PRNewswire-FirstCall/ -- ...s that it has appointed William,(Bill) Federici, 4...to five,members., Mr. Federici joined West Pharma...ncial Officer in August of 2003. Under his financi... grown to more than $1.0 billion from,$300 million...
(Date:10/10/2008)...RICHMOND, Va., Oct. 10 /PRNewswire/ -- Do you thin...Can,t get around town? Attend the October,17 open ...e Blind and,Vision Impaired, and see how instructo...o lead productive, fulfilling lives through non-vi..., located at 401 Azalea Avenue, is holding an open...
(Date:10/10/2008)... Upon the completion of a hig...vision of CDM Media proudly announces their next b...ief information technology executives in healthcar...it will launch May 10-12, 2009 at the Four Seasons... Honolulu, HI (PRWEB) October 11, 2008 -- Upon ...
Breaking Medicine News(10 mins):Health News:Antibiotics May Not Cause Diarrheal Bacteria 2Health News:Synvista Therapeutics Appoints William Federici to its Board of Directors 2Health News:Synvista Therapeutics Appoints William Federici to its Board of Directors 3Health News:Virginia Rehabilitation Center for the Blind and Vision Impaired Celebrates Opening of New Student Dormitory 2Health News:CIO Healthcare Summit Announces Dates and VIP Delegates 2
...at awards and accomplishments could have a profoun...car winners have been on an average found to live ...t the race and went home and empty-handed. The in...d actresses can be found in the latest issue of th...
...lular biologist who is the principle investigator ...of taste cells would help them to discover molecul...stes.// Researchers from the Monell Chemical Sense...eceptor cells outside the body. They have also bee...
...ly harms the teeth by way of discoloring them, it ...nal treatment, according to a new study // appeari...earch. "The findings substantiate what most of u...o your health," Elizabeth Krall Kaye, PhD, MPH, ep...
...PhD, with the Bradley Hasbro Children's Research C... effect of asthma on children. She said that // th...ving skills may be less likely to have their asthm...inspite of facing the stress related to urban scen...
Other Medicine News:Health News:Oscar Winners Live Longer Than Co-Competitors 2Health News:Functional Taste Cells Cultured In Vitro 2
...ragon CZE 2000 Capillary Electrophoresis System us...erum protein electrophoresis (SPE), urine protein ...ctrophoresis (IFE/s) for fast and accurate analysi... no sample preparation and no staining to process ...
The CellTracks® Analyzer II is a semi-automated fluorescence microscope used to enumerate fluorescently labeled cells that are immunomagnetically selected and aligned. The product consists of the
These unique Acid Fast Control Slides simulate a clinical sputum smear with appropriate background material. Slides have two wells containing a positive and negative smear. Can be used with Kinyoun (
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques.
Medicine Products: